2022-11-011 - IMMETCOLS - Development and Validation of an immune-metabolic signature (IMMETCOLS) to increase immunotherapy efficacy colorectal cancer patients
Acronim & Gínjol codes
IMMETCOLS
2022-11-011
Main technology offer
Classifier based on immune-metabolic signature. Prediction of targetable metabolic vulnerabilities specific for clusters, with the potential to synergize with ICI therapies
Ownership
Public Partners
Readiness Level
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
MIN
1
2
3
4
5
6
7
8
9
10
MAX
Impact: ESG & SDG Goals
Improve the early stratification of Cancer patient for the correct therapeutic management Reduce the cost for the National healthcare system Improve the quality of lives of patients
Market Data
Problem: Immune check-point inhibitor (ICI) treatment efficacy ranges from 30-40% in sensitive tumors to <5% in immuneresistant tumors. Current Predictive methods have low sensitivity and poor specificity identifying patients that could benefit from ICI Treatment. Solution: IMMETCOL is a 10-gene signature that classifies patients with solid tumors in 3 different clusters depending on the immuno-metabolic profile, allowing the clinician to choose the best treatment strategy for each patient.
0
0
0
Development of an algorithm based on 10-gene signature for treatment stratification in Cancer patients
There is a need on the Identification ICI responder patients better than the Standard of Care. The national healthcare system need to reduce the cost related to non-responder patients as well as provide new therapeutics approaches to non-responder patients.
Patients suffering from a cancer in order to classify them regarding the metabolic characteristics to offer them an efficient treatment strategy.
Funding
Actually, the project has funds to validate the first prototype of the Point of Care in a rellevant clinical environment We need a partner in order to define the regulatory roadmap and also to support the next clinical phases and the regulatory affairs.
License Agreement with an industrial Partner. Co-development Agreement with an Industrial Partner
The 10 gene signature have been defined as a potential predictive biomarker to treatment.
Technology Status
New algorithms based-biomarker capable to stratify patients suffering from cancer regarding their metabolic signature as a new approach for treatment management.
Signature Validation in a rellevant environment PoC by using organoids Business strategy and possible Partners for a co-development
Priority patent application was filed on 20 August 2021. A PCT extension was filed on August 2022 with code PCT/EP2022/073151. Patent will enter in National Phases in December 2023
Intellectual Property Rights protected by a patent application. Apart from Gínjol 11th, the Project has grant some other fundings from Instituto de Salud Carlos III.
Additional information
Patents: PCT/EP2022/073151
The IMMETCOLS signature provides a simplified classifier of tumors from diverse origins, yielding three clusters with distinct immune-metabolic profiles, representing a new predictive tool for patient selection for specific immune-metabolic therapeutic approaches.